Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
Portfolio Pulse from Benzinga Newsdesk
Asahi Kasei has announced that it controls over 90% of Calliditas Therapeutics and plans to delist its common shares from Nasdaq Stockholm and its American Depositary Shares from the Nasdaq Global Select Market.
September 03, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Calliditas Therapeutics is set to be delisted from Nasdaq Stockholm and Nasdaq Global Select Market following Asahi Kasei's acquisition of over 90% control.
The delisting of Calliditas Therapeutics from major stock exchanges is likely to negatively impact its stock price in the short term as it reduces liquidity and market visibility. Investors may react by selling shares, leading to a potential decrease in stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100